OBJECTIVE: To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. METHODS: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) II, a 2-year randomized, rater-blinded, active-controlled, head-to-head, phase 3 trial, compared efficacy and safety of alemtuzumab 12 mg with subcutaneous interferon-β-1a (SC IFN-β-1a) 44 μg in patients with RRMS. Prespecified and post hoc disability outcomes based on Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC), and Sloan low-contrast letter acuity (SLCLA) are reported, focusing on improvement of preexisting disability in addition to slowing of disability accumulation. RESULTS: Alemtuzumab-treated patients were more likely than SC IFN-β-1a-treated patients to show improvement in EDSS scores (p < 0.0001) on all 7 functional systems. Significantly more alemtuzumab patients demonstrated 6-month confirmed disability improvement. The likelihood of improved vs stable/worsening MSFC scores was greater with alemtuzumab than SC IFN-β-1a (p = 0.0300); improvement in MSFC scores with alemtuzumab was primarily driven by the upper limb coordination and dexterity domain. Alemtuzumab-treated patients had more favorable changes from baseline in SLCLA (2.5% contrast) scores (p = 0.0014) and MSFC + SLCLA composite scores (p = 0.0097) than SC IFN-β-1a-treated patients. CONCLUSIONS: In patients with RRMS and inadequate response to prior disease-modifying therapies, alemtuzumab provides greater benefits than SC IFN-β-1a across several disability outcomes, reflecting improvement of preexisting disabilities. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence (based on rater blinding and a balance in baseline characteristics between arms) that alemtuzumab modifies disability measures favorably compared with SC IFN-β-1a.

From Queen Mary University of London

Neurology. 87(19):1966. PubMed

Zobrazit více v PubMed

Gold R, Kappos L, Arnold DL, et al. . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098–1107. PubMed

Johnson KP, Brooks BR, Cohen JA, et al. . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial: The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268–1276. PubMed

Kappos L, Radue EW, O'Connor P, et al. . A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387–401. PubMed

O'Connor P, Wolinsky JS, Confavreux C, et al. . Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293–1303. PubMed

Polman CH, O'Connor PW, Havrdova E, et al. . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899–910. PubMed

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498–1504. PubMed

The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655–661. PubMed

Julian LJ, Vella L, Vollmer T, Hadjimichael O, Mohr DC. Employment in multiple sclerosis: exiting and re-entering the work force. J Neurol 2008;255:1354–1360. PubMed PMC

Naci H, Fleurence R, Birt J, Duhig A. The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. J Med Econ 2010;13:78–89. PubMed

Rudick RA, Cutter G, Baier M, et al. . Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001;56:1324–1330. PubMed

Coles AJ, Fox E, Vladic A, et al. . Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011;10:338–348. PubMed

Coles AJ, Twyman CL, Arnold DL, et al. . Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829–1839. PubMed

Hobart J, Freeman J, Thompson A. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000;123:1027–1040. PubMed

Kragt JJ, Nielsen JM, van der Linden FA, Polman CH, Uitdehaag BM. Disease progression in multiple sclerosis: combining physicians' and patients' perspectives? Mult Scler 2011;17:234–240. PubMed

Phillips JT, Giovannoni G, Lublin FD, et al. . Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler 2011;17:970–979. PubMed

Cutter GR, Baier ML, Rudick RA, et al. . Development of a Multiple Sclerosis Functional Composite as a clinical trial outcome measure. Brain 1999;122:871–882. PubMed

Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter G. Administration and Scoring Manual for the Multiple Sclerosis Functional Composite (MSFC). New York: National Multiple Sclerosis Society; 2001.

Rudick RA, Polman CH, Cohen JA, et al. . Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler 2009;15:984–997. PubMed

Talman LS, Bisker ER, Sackel DJ, et al. . Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol 2010;67:749–760. PubMed PMC

Balcer LJ, Baier ML, Cohen JA, et al. . Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003;61:1367–1373. PubMed

Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000;68:450–457. PubMed PMC

Jones JL, Anderson JM, Phuah CL, et al. . Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain 2010;133:2232–2247. PubMed

Kragt JJ, van der Linden FA, Nielsen JM, Uitdehaag BM, Polman CH. Clinical impact of 20% worsening on Timed 25-Foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult Scler 2006;12:594–598. PubMed

Lachin JM. Power and sample size evaluation for the McNemar test with application to matched case-control studies. Stat Med 1992;11:1239–1251. PubMed

Compston DA, Confavreux C, Lassmann H, et al. . McAlpine's Multiple Sclerosis. 4th ed. London: Elsevier; 2006.

Kerschensteiner M, Gallmeier E, Behrens L, et al. . Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999;189:865–870. PubMed PMC

Menge T, Stüve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology 2014;83:87–97. PubMed

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program